Xenetic Biosciences, Inc.
XBIO Healthcare Biotechnology
Xenetic Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 19.0% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS grew 8.89% and free cash flow fell 128.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow XBIO
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
4.11 | 5.60 | 0.64 | 10.37 | 11.53 | 18.24 | 13.10 | 8.98 | 6.17 | 7.88 |
Receivables |
3.00 | — | — | — | — | — | — | — | — | — |
Total current assets |
8.34 | 5.88 | 1.19 | 11.09 | 12.37 | 18.72 | 13.65 | 9.59 | 6.59 | 8.05 |
Property, Plant, Equpment (Net) |
0.04 | 0.03 | 0.01 | 0.00 | — | — | — | — | — | — |
Goodwill and Intangible Assets (Total) |
12.53 | 12.53 | 12.53 | 9.24 | — | — | — | — | — | — |
Long-term assets (Other) |
0.07 | 0.72 | 0.71 | 1.21 | 0.81 | 1.09 | 1.07 | 1.02 | 0.31 | 0.31 |
Total non-current assets |
12.64 | 13.28 | 13.24 | 10.46 | 0.81 | 1.09 | 1.07 | 1.02 | 0.31 | 0.31 |
Total Assets |
20.97 | 19.16 | 14.43 | 21.55 | 13.18 | 19.82 | 14.72 | 10.61 | 6.90 | 8.36 |
Accounts Payable |
1.01 | 0.79 | 0.93 | 0.93 | 0.33 | 0.36 | 0.29 | 0.24 | 0.28 | 0.26 |
Accrued Expenses |
0.84 | 1.14 | 0.67 | 0.48 | 0.61 | 1.06 | 0.79 | 0.57 | 0.61 | 0.71 |
Total current liabilities |
1.87 | 1.94 | 1.60 | 1.42 | 0.94 | 1.42 | 1.07 | 0.81 | 0.89 | 0.97 |
Long Term Tax Liability (Deferred) |
2.92 | 2.92 | 2.92 | 2.92 | — | — | — | — | — | — |
Non-current Liabilities (Other) |
0.02 | — | 0.00 | 0.00 | 0.03 | — | — | — | — | — |
Total non-current liabilities |
2.94 | 2.92 | 2.92 | 2.92 | 0.03 | — | — | — | — | — |
Total liabilities |
4.80 | 4.86 | 4.52 | 4.33 | 0.96 | 1.42 | 1.07 | 0.81 | 0.89 | 0.97 |
Additional Paid In Capital |
163.52 | 165.25 | 168.17 | 188.24 | 194.13 | 205.95 | 207.77 | 208.05 | 208.23 | 212.29 |
Preferred Stock (Total) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Common Stock (Net) |
0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Retained Earnings |
(142.34) | (145.93) | (153.23) | (166.01) | (176.90) | (182.55) | (189.10) | (193.23) | (197.19) | (199.88) |
Treasury Stock |
5.28 | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 |
Common Equity (Total) |
16.17 | 14.30 | 9.91 | 17.21 | 12.21 | 18.39 | 13.64 | 9.79 | 6.01 | 7.39 |
Shareholders Equity (Total) |
16.17 | 14.30 | 9.91 | 17.21 | 12.22 | 18.39 | 13.65 | 9.80 | 6.01 | 7.40 |
Shareholders Equity and Liabilities (Total) |
20.97 | 19.16 | 14.43 | 21.55 | 13.18 | 19.82 | 14.72 | 10.61 | 6.90 | 8.36 |
Shares (Common) |
0.07 | 0.07 | 0.08 | 0.61 | 0.87 | 1.34 | 1.52 | 1.54 | 1.54 | 2.29 |
Shares (Preferred) |
0.03 | 0.03 | 0.28 | 0.28 | 0.28 | 0.28 | 2.77 | 1.80 | 1.80 | 1.45 |
Shareholders Equity (Tangible) |
3.64 | 1.78 | (2.61) | 7.97 | 12.22 | 18.39 | 13.65 | 9.80 | 6.01 | 7.40 |
Net Debt |
(4.11) | (5.60) | (0.64) | (10.37) | (11.53) | (18.24) | (13.10) | (8.98) | (6.17) | (7.88) |
Total Debt |
— | — | — | 0.02 | 0.04 | 0.03 | — | — | — | — |